Despite requiring substantial resources, lifestyle programs are unlikely to be successful without including a strong behavioral change component, one commenter noted.

Add Yahoo as a preferred source to see more of our stories on Google. Eli Lilly has unveiled a new weight loss drug that appears to be delivering the highest weight loss yet in clinical trials while ...

Eli Lilly on Thursday said its next-generation obesity drug delivered what appears to be the highest weight loss yet in a late-stage trial while reducing knee arthritis pain, clearing the first of ...

In a phase 3 trial, Eli Lilly’s experimental drug retatrutide delivered an average 28.7% weight loss and reduced pain among adults with obesity or overweight and knee osteoarthritis. The trial ...

The drugmaker said its "triple G" drug led to significant weight loss and a reduction in pain for patients who have obesity and overweight Eli Lilly's "triple g" drug helped patients lose about 28.7% ...

We summarized existing research on weight loss medications in rheumatic disease and their potential for improving quality of ...

The triple hormone receptor agonist retatrutide reduced body weight and improved pain and physical function in obese/overweight patients with knee osteoarthritis. Topline results were announced from a ...

One of Eli Lilly’s most promising new obesity drugs helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis. The drug giant’s LLY stock was ...